P40 is the best marker for diagnosing pulmonary squamous cell carcinoma: Comparison with p63, cytokeratin 5/6, desmocollin-3, and Sox2

Applied Immunohistochemistry and Molecular Morphology

Volumn 22, Issue 5, 2014, Pages 377-382

  Tatsumori, Takahiro ^a,b   Tsuta, Koji ^a   Masai, Kyohei ^a   Kinno, Tomoaki ^a   Taniyama, Tomoko ^a   Yoshida, Akihiko ^a   Suzuki, Kenji ^b   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adenocarcinoma; Lung; p63; Squamous cell carcinoma; Np63

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; DESMOCOLLIN; DESMOCOLLIN 3; PROTEIN P40; PROTEIN P63; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; CKAP4 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; CYCLIN-DEPENDENT KINASE-ACTIVATING KINASE; DSC3 PROTEIN, HUMAN; MEMBRANE PROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ARTICLE; CANCER DIAGNOSIS; CARCINOID; HUMAN; IMMUNOREACTIVITY; LARGE CELL NEUROENDOCRINE CARCINOMA; LUNG ADENOCARCINOMA; LUNG SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALIGNANT MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; CARCINOID TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MESOTHELIOMA; METABOLISM; SENSITIVITY AND SPECIFICITY;

CARCINOID TUMOR; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CYCLIN-DEPENDENT KINASES; DESMOCOLLINS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; KERATIN-6; LUNG NEOPLASMS; MEMBRANE PROTEINS; MESOTHELIOMA; SENSITIVITY AND SPECIFICITY; SOXB1 TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900437078     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e3182980544     Document Type: Article

References (23)

1. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinomas and large cell carcinomas compared to surfactant proteins a and b. Histopathology. 2000; 36: 8-16.
2. Kaufmann O, Fietze E, Mengs J, et al. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol. 2001; 116: 823-830.
3. Pelosi G, Pasini F, Olsen Stenholm C, et al. P63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? J Pathol. 2002; 198: 100-109.
4. Reis-Filho JS, Simpson PT, Martins A, et al. Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using tarp-4 multi-tumor tissue microarray. Virchows Arch. 2003; 443: 122-132.
5. Wu M, Szporn AH, Zhang D, et al. Cytology applications of p63 and ttf-1 immunostaining in differential diagnosis of lung cancers. Diag Cytopathol. 2005; 33: 223-227.
6. Wu M, Wang B, Gil J, et al. P63 and ttf-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Am J Clin Pathol. 2003; 119: 696-702.
7. Kalhor N, Zander DS, Liu J. Ttf-1 and p63 for distinguishing pulmonary small-cell carcinoma from poorly differentiated squamous cell carcinoma in previously pap-stained cytologic material. Mod Pathol. 2006; 19: 1117-1123.
8. Kargi A, Gurel D, Tuna B. The diagnostic value of ttf-1, ck 5/6, and p63 immunostaining in classification of lung carcinomas. Appl Immunohistochem Mol Morphol. 2007; 15: 415-420.
9. Rekhtman N, Ang DC, Sima CS, et al. Immunohistochemical algorithm for differentiation of lung adenocarcinoma and squamous cell carcinoma based on large series of whole-tissue sections with validation in small specimens. Mod Pathol. 2011; 24: 1348-1359.
10. Terry J, Leung S, Laskin J, et al. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol. 2010; 34: 1805-1811.
11. Mukhopadhyay S, Katzenstein AL. Subclassification of non-small cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing ttf-1, napsin a, p63, and ck5/6. Am J Surg Pathol. 2011; 35: 15-25.
12. Tsuta K, Tanabe Y, Yoshida A, et al. Utility of 10 immunohistochemical markers including novel markers (desmocollin-3, glypican 3, s100a2, s100a7, and sox-2) for differential diagnosis of squamous cell carcinoma from adenocarcinoma of the lung. J Thorac Oncol. 2011; 6: 1190-1199.
13. Righi L, Graziano P, Fornari A, et al. Immunohistochemical subtyping of nonsmall cell lung cancer not otherwise specified in fine-needle aspiration cytology: a retrospective study of 103 cases with surgical correlation. Cancer. 2011; 117: 3416-3423.
14. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Pathol. 2002; 198: 417-427.
15. Bishop JA, Teruya-Feldstein J, Westra WH, et al. P40 (deltanp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma. Mod Pathol. 2012; 25: 405-415.
16. Pelosi G, Rossi G, Bianchi F, et al. Immunhistochemistry by means of widely agreed-upon markers (cytokeratins 5/6 and 7, p63, thyroid transcription factor-1, and vimentin) on small biopsies of non-small cell lung cancer effectively parallels the corresponding profiling and eventual diagnoses on surgical specimens. J Thorac Oncol. 2011; 6: 1039-1049.
17. Nonaka D. A study of deltanp63 expression in lung non-small cell carcinomas. Am J Surg Pathol. 2012; 36: 895-899.
18. Masai K, Tsuta K, Kawago M, et al. Expression of squamous cell carcinoma markers and adenocarcinoma markers in primary pulmonary neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol. 2013; 21: 292-297.
19. Travis WD, Bramblla E, Muller-Hermelink HK, et al. Pathology and Genetics of Tumors of the Lung, Pleura, Thymus and Heart. Lyon, France: IARC Press; 2004.
20. Miyanaga A, Honda K, Tsuta K, et al. Diagnostic and prognostic significance of the alternatively spliced actn4 variant in high-grade neuroendocrine pulmonary tumours. Annals Oncol. 2013; 24: 84-90.
21. Au NH, Gown AM, Cheang M, et al. P63 expression in lung carcinoma: a tissue microarray study of 408 cases. Appl immunohistochem mol morphol. 2004; 12: 240-247.
22. Ye J, Findeis-Hosey JJ, Yang Q, et al. Combination of napsin a and ttf-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung. Appl Immunohistochem Mol Morphol. 2011; 19: 313-317.
23. Ordonez NG. The diagnostic utility of immunohistochemistry in distinguishing between epithelioid mesotheliomas and squamous carcinomas of the lung: a comparative study. Mod Pathol. 2006; 19: 417-428.